6<strong>Update</strong> <strong>in</strong> <strong>Anaesthesia</strong>which may lead to ventricular tachycardia or fibrillation.Less serious side-effects are nausea, vomit<strong>in</strong>g, visualdisturbance and headache, but these may precede toxicity.Plasma levels can be measured to ensure therapeutic levelsare not exceeded. Some factors enhance toxicity, such ashypokalaemia, hypomagnesaemia, hypercalcaemia,hypoxia, acidosis and myocardial ischaemia. The dose ofdigox<strong>in</strong> must be reduced <strong>in</strong> renal failure, and if there is aknown drug <strong>in</strong>teraction (e.g. amiodarone, verapamil,qu<strong>in</strong>id<strong>in</strong>e).Adenos<strong>in</strong>e is a naturally occurr<strong>in</strong>g molecule which is ametabolite of adenos<strong>in</strong>e monophosphate. It acts via specificadenos<strong>in</strong>e receptors to cause coronary vasodilation andreduced conduction at the s<strong>in</strong>o-atrial and atrioventricularnodes. It is particularly useful <strong>in</strong> treat<strong>in</strong>g re-entrysupraventricular tachycardias, but has no effect onventricular tachycardia. It has a very short half-life (10seconds), and is given by rapid <strong>in</strong>travenous <strong>in</strong>jection. Theshort duration of action and low <strong>in</strong>cidence of adverseeffects makes adenos<strong>in</strong>e useful <strong>in</strong> diagnos<strong>in</strong>g broadcomplex tachycardias as either supraventricular orventricular <strong>in</strong> orig<strong>in</strong>.HYPERTENSIONPathophysiologyIn most patients with raised blood pressure there is noobvious cause; this is called essential hypertension. Thepathogenesis of hypertension is complex but the follow<strong>in</strong>gfactors have been implicated: (a) <strong>in</strong>creased sympatheticactivity, (b) sodium retention and an <strong>in</strong>creased circulat<strong>in</strong>gvolume, (c) <strong>in</strong>creased vascular rigidity and reactivity, (d)<strong>in</strong>creased circulat<strong>in</strong>g catecholam<strong>in</strong>es and activation of theren<strong>in</strong>-angiotens<strong>in</strong>-aldosterone system, and (e) abnormalbaroreceptor responses. High blood pressure is associatedwith a reduced life expectancy, because of an <strong>in</strong>creasedrisk of stroke and coronary artery disease; also other endorgandisease, such as ret<strong>in</strong>opathy and renal failure.Anti-hypertensive drugsArterial pressure <strong>in</strong>creases with age and therefore there isno absolute value at which treatment should be started.Untreated hypertension leads to <strong>in</strong>creased perioperativemorbidity and mortality. In the presence of othercardiovascular risk factors such as diabetes,hyperlipidaemia or smok<strong>in</strong>g, the threshold for treatmentshould be lower. As a general rule elective surgery shouldbe delayed if the rest<strong>in</strong>g diastolic pressure is greater than<strong>11</strong>0 mm Hg.Based on the pathogenesis of essential hypertensiondescribed above, there are different classes of antihypertensivedrugs. They are used alone or <strong>in</strong> variouscomb<strong>in</strong>ations. Diuretics (either thiazide or loop diuretics)reduce sodium and extracellular volume and are often thefirst-l<strong>in</strong>e drugs. Another important group are thevasodilators, such as ACE-<strong>in</strong>hibitors, calciumantagonists, and the direct vasodilator hydralaz<strong>in</strong>e.Adrenergic block<strong>in</strong>g agents such as beta-blockers andthe alpha 1-receptor antagonist prazos<strong>in</strong> are also widelyused.Treatment of severe hypertensionAlthough severe hypertension (e.g. diastolic pressure above140 mmHg) can often be managed with oral treatment,this may not be suitable for the peri-operative patient, orwhen there are life threaten<strong>in</strong>g complications such asencephalopathy or heart failure. In these situations bloodpressure can be controlled with the <strong>in</strong>travenous agentsdescribed below, which have the advantage of a rapidonset of action. The dose should be titrated aga<strong>in</strong>st theresponse, because rapid falls <strong>in</strong> blood pressure can causereduced cerebral perfusion and <strong>in</strong>farction. Before start<strong>in</strong>gsuch treatments <strong>in</strong> the peri-operative patient, factors whichmay be aggravat<strong>in</strong>g the hypertension should be identifiedand treated. These <strong>in</strong>clude <strong>in</strong>adequate analgesia,hypothermia, hypoxia and withdrawal of normal antihypertensivedrugs.Labetalol This drug is both an alpha-1 and beta adrenergicreceptor blocker, with a ratio of alpha:beta activity of about1:5. As well as emergency treatment of severehypertension, it is also used <strong>in</strong> the treatment of preeclampsiaand to provide hypotension for certa<strong>in</strong> surgicalprocedures. Labetalol has a half-life of between three andsix hours depend<strong>in</strong>g on the dose given, and can causehepatic damage, even after short periods of treatment. Itis given <strong>in</strong>travenously <strong>in</strong> <strong>in</strong>crements of 5-10mg up to amaximum of 200mg.Hydralaz<strong>in</strong>e is an arteriolar vasodilator and thus reducessystemic vascular resistance, caus<strong>in</strong>g a reflex tachycardia.It is widely used <strong>in</strong> hypertension associated with preeclampsia,but its onset of action may be up to 20 m<strong>in</strong>utes.Headache, nausea, vomit<strong>in</strong>g, and flush<strong>in</strong>g are common sideeffects, and it can cause ang<strong>in</strong>a <strong>in</strong> patients with ischaemicheart disease. In the obstetric patient the aim is to keepthe blood pressure below 170/<strong>11</strong>0 mmHg, us<strong>in</strong>g doses of5-10mg which can be repeated after 30 m<strong>in</strong>utes ifnecessary.
<strong>Update</strong> <strong>in</strong> <strong>Anaesthesia</strong> 7Sodium Nitroprusside (SNP) This acts directly onvascular smooth muscle and causes arteriolar and venousdilation. As a consequence blood pressure falls and a reflextachycardia occurs. SNP acts very rapidly and the durationof action is only a few m<strong>in</strong>utes. The drug can producetoxicity by production of cyanide, and there are maximumrecommended doses for both acute and longer term use.GTN, which is discussed elsewhere, can also be used forrapid control of high blood pressure.CARDIOVASCULAR EFFECTS OFANAESTHETICSInhalational agentsAll volatile agents depress myocardial contractility, but thiseffect is most marked with halothane and enflurane. Withthe exception of halothane they all decrease systemicvascular resistance, contribut<strong>in</strong>g further to the fall <strong>in</strong> bloodpressure and result<strong>in</strong>g <strong>in</strong> a reflex tachycardia. Dur<strong>in</strong>ghalothane anaesthesia systemic vascular resistance isunchanged and, due to vagal stimulation, bradycardias andnodal rhythms are common. Unlike other volatile agentshalothane sensitises the heart to the arrhythmogenic effectsof catecholam<strong>in</strong>es, and ventricular ectopics are often seen.High levels of circulat<strong>in</strong>g catecholam<strong>in</strong>es can causeventricular tachycardia or ventricular fibrillation, especially<strong>in</strong> the presence of hypercarbia, which can occur <strong>in</strong> a patientspontaneously breath<strong>in</strong>g halothane. Ether causessympathetic stimulation, catecholam<strong>in</strong>e release and, to acerta<strong>in</strong> degree, vagus nerve blockade. As a result there isan <strong>in</strong>crease <strong>in</strong> cardiac output, heart rate and systemicvascular resistance, so blood pressure is well ma<strong>in</strong>ta<strong>in</strong>ed.Intravenous <strong>in</strong>duction agentsMost <strong>in</strong>duction agents are cardiovascular depressants. Thegreatest effect is seen with propofol, which may cause amarked fall <strong>in</strong> blood pressure, systemic vascular resistanceand heart rate, the latter due to central vagal stimulation.Thiopentone has similar effects, although less pronounced,and there is a reflex tachycardia mediated by thebaroreceptor reflex. This can result <strong>in</strong> <strong>in</strong>creased myocardialoxygen consumption and a consequent <strong>in</strong>crease <strong>in</strong>coronary blood flow. Benzodiazep<strong>in</strong>es such as midazolamand diazepam are associated with cardiovascular stability,and only high doses will cause cardiovascular depression.Etomidate provides the most cardiovascular stability, withonly slight changes <strong>in</strong> haemodynamic variables. Etomidatehas little effect on myocardial oxygen balance. Ketam<strong>in</strong>e,<strong>in</strong> contrast to other <strong>in</strong>duction agents, is a potentcardiovascular stimulant by <strong>in</strong>creas<strong>in</strong>g sympathetic nervousdischarge, although its direct effect on the myocardium isnegatively <strong>in</strong>otropic. On <strong>in</strong>duction there is a marked rise<strong>in</strong> heart rate and blood pressure caused by central nervousstimulation and an <strong>in</strong>crease <strong>in</strong> circulat<strong>in</strong>g catecholam<strong>in</strong>es.ANAESTHESIA AND CHRONIC RENAL FAILUREDr Penny Stewart, Sydney, Australia and Dr Debbie Harris, Frenchay Hospital, UKChronic Renal Failure (CRF) may be caused by primaryrenal disease or by systemic diseases which also affectthe kidney. A decrease <strong>in</strong> nephron function occurs andcan lead to a typical cl<strong>in</strong>ical pattern. CRF only becomesbiochemically evident when less than 40% of the nephronsare function<strong>in</strong>g. Dialysis (either peritoneal or haemodialysis)is generally not required until less than 10% of nephronsare function<strong>in</strong>g. Patients with CRF are more likely to haveassociated atheroma formation and hypertension.Preoperative Assessment and Treatment of MedicalProblems <strong>in</strong> Renal FailureThe follow<strong>in</strong>g factors should be considered when assess<strong>in</strong>ga patient for anaesthesia prior to either an elective oremergency procedure.Fluid balance In CRF sodium and water excretion isrelatively fixed and often reduced. The kidneys can havedifficulty handl<strong>in</strong>g both large fluid loads and dehydration.The degree of hydration should be assessed <strong>in</strong> the usualway us<strong>in</strong>g sk<strong>in</strong> turgor, exam<strong>in</strong>ation of the mucousmembranes, jugular venous pressure, presence ofdependent oedema and presence of pulmonary oedemaon auscultation. Invasive measurement of central venouspressure may occasionally be <strong>in</strong>dicated. Many patientson dialysis regimens will know their normal hydrated weightand their fluid allowance per day.The patient must be normovolaemic prior to surgery. Fluidresuscitation should normally be with normal sal<strong>in</strong>e but ifthere has been blood loss this might also have to bereplaced.